Cytokinetics Inc (NASDAQ: CYTK) is -31.70% lower on its value in year-to-date trading and has touched a low of $31.67 and a high of $64.61 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CYTK stock was last observed hovering at around $31.69 in the last trading session, with the day’s gains setting it 0.44%.
Currently trading at $32.13, the stock is -15.12% and -20.31% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.26 million and changing 1.37% at the moment leaves the stock -34.38% off its SMA200. CYTK registered -50.77% loss for a year compared to 6-month loss of -42.11%.
The stock witnessed a -15.11% gain in the last 1 month and extending the period to 3 months gives it a -23.88%, and is -12.38% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.07% over the week and 5.30% over the month.
Cytokinetics Inc (CYTK) has around 498 employees, a market worth around $3.84B and $19.22M in sales. Profit margin for the company is -3201.47%. Distance from 52-week low is 1.45% and -50.27% from its 52-week high. The company has generated returns on investments over the last 12 months (-125.03%).
The EPS is expected to shrink by -8.77% this year.
Cytokinetics Inc (CYTK) Top Institutional Holders
The shares outstanding are 119.22M, and float is at 116.28M with Short Float at 12.45%.
The top institutional shareholder in the company is BLACKROCK INC. with over 14.67 million shares valued at $794.97 million. The investor’s holdings represent 13.4317% of the CYTK Shares outstanding. As of 2024-06-30, the second largest holder is FMR LLC with 11.52 million shares valued at $624.32 million to account for 10.5485 of the shares outstanding. The other top investors are VANGUARD GROUP INC which holds 11.44 million shares representing 10.4702% and valued at over $619.69 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 7.4503 of the shares totaling 8.14 million with a market value of $440.95 million.
Cytokinetics Inc (CYTK) Insider Activity
The most recent transaction is an insider sale by Malik Fady Ibraham, the company’s EVP Research & Development. SEC filings show that Malik Fady Ibraham sold 2,000 shares of the company’s common stock on May 06 ’25 at a price of $35.01 per share for a total of $70020.0. Following the sale, the insider now owns 0.14 million shares.
Cytokinetics Inc disclosed in a document filed with the SEC on May 05 ’25 that Callos Andrew (EVP, Chief Commercial Officer) sold a total of 4,002 shares of the company’s common stock. The trade occurred on May 05 ’25 and was made at $36.68 per share for $0.15 million. Following the transaction, the insider now directly holds 60687.0 shares of the CYTK stock.
Still, SEC filings show that on Apr 29 ’25, Blum Robert I (President & CEO) disposed off 5,000 shares at an average price of $40.96 for $0.2 million. The insider now directly holds 417,629 shares of Cytokinetics Inc (CYTK).
